A clinical briefing on the Aquasol E shortage for healthcare providers. Includes timeline, prescribing implications, alternatives, and tools.
The shortage of Aquasol E — a water-soluble formulation of Vitamin E (D-Alpha Tocopherol) — continues to affect patient care across specialties. For providers who prescribe this product for patients with fat malabsorption syndromes, premature infants, or Vitamin E deficiency, the limited supply creates real clinical challenges.
This briefing covers the current state of the shortage, the timeline of events, prescribing implications, and practical tools for helping your patients access treatment.
The Aquasol E supply disruption is not a recent development. Here's how we got here:
The discontinuation of commercially available water-soluble Vitamin E formulations has several clinical implications:
When patients are switched to alternative formulations or compounded products, consider:
Different water-soluble Vitamin E formulations may have varying bioavailability. When switching a patient from Aquasol E (50 IU/mL) to an alternative:
In 2026, the supply landscape for water-soluble Vitamin E includes:
Compounding pharmacies represent the most reliable and consistent source of water-soluble Vitamin E in 2026. PCCA-accredited compounding pharmacies can prepare custom formulations per prescription specifications.
When writing compounding prescriptions, specify:
The limited supply has affected both cost and access:
Insurance coverage varies significantly. Many plans do not cover OTC vitamin supplements, but prescription formulations with documented medical necessity may be approved. Medicaid coverage is more common for pediatric patients and those with diagnosed malabsorption syndromes. Prior authorization may be required.
For patients facing cost barriers, organizations like NeedyMeds and RxAssist may offer assistance resources.
Several resources can help streamline the process of locating supply for your patients:
Share the patient-facing version with your patients: Aquasol E Shortage Update: What Patients Need to Know.
There is currently no public indication that a major manufacturer plans to reintroduce Aquasol E or a directly equivalent water-soluble Vitamin E oral solution. The small market size and manufacturing complexity continue to deter new entrants.
In the meantime, providers should:
The Aquasol E shortage is a protracted supply failure that disproportionately affects vulnerable patient populations. While commercial alternatives and compounding options exist, they require proactive effort from prescribers to ensure continuity of care. Staying informed, maintaining pharmacy relationships, and using availability tools like Medfinder can help close the gap between what patients need and what's available.
Related provider resources:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
